Biomarker bei Herzinsuffizienz: klinischer
Stellenwert belegt?

T. Kempf; K. C. Wollert

doi:10.1055/s-0029-1220224

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2009; 134(15): 740-746
DOI: 10.1055/s-0029-1220224

Übersicht | Review article

Kardiologie, Labormedizin
© Georg Thieme Verlag KG Stuttgart · New York

Biomarker bei Herzinsuffizienz: klinischer Stellenwert belegt?

Biomarkers in heart failure: are they clinically useful?T. Kempf¹ , K. C. Wollert¹

¹Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover

Abstract

Schlüsselwörter

Biomarker - Herzinsuffizienz - natriuretische Peptide - BNP - NT-proBNP - Troponin - GDF-15

Keywords

biomarkers - heart failure - natriuretic peptides - BNP - NT-proBNP - troponin - GDF-15

Volltext

Referenzen

Literatur

1 Anand I S. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008; 52 501-511
2 Anand I S, Kuskowski M A, Rector T S. et al . Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005; 112 1121-1127
3 Anker S D, Doehner W, Rauchhaus M. et al . Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107 1991-1997
4 Babuin L, Jaffe A S. Troponin: the biomarker of choice for the detection of cardiac injury. Can Med Assoc J. 2005; 173 1191-1202
5 Braunwald E. Biomarkers in heart failure. New Engl J Med. 2008; 358 2148-2159
6 Bursi F, Weston S A, Redfield M M. et al . Systolic and diastolic heart failure in the community. JAMA. 2006; 296 2209-2216
7 Pfisterer M, Buser P, Rickli H. et al . BNP-guided vs symptom-guided heart failure therapy: the trial of Intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009; 301 383-392
8 Cowie M R, Struthers A D, Wood D A. et al . Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997; 350 1349-1353
9 Daniels L B, Maisel A S. Natriuretic peptides. J Am Coll Cardiol. 2007; 50 2357-2368
10 Dickstein K, Cohen-Solal A, Filippatos G. et al . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29 2388-2442
11 Fonarow G C, Adams Jr K F, Abraham W T, Yancy C W, Boscardin W J. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293 572-580
12 Forman D E, Butler J, Wang Y. et al . Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43 61-67
13 Gerszten R E, Wang T J. The search for new cardiovascular biomarkers. Nature. 2008; 451 949-952
14 Ginsburg G S, McCarthy J J. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001; 19 491-496
15 Goldsmith S R. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol. 2005; 95 14B-23B
16 Gustafsson F, Steensgaard-Hansen F, Badskjaer J, Poulsen A H, Corell P, Hildebrandt P. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail. 2005; 11 S15-20
17 Hare J M, Mangal B, Brown J. et al . Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008; 51 2301-2309
18 Heywood J T, Fonarow G C, Costanzo M R, Mathur V S, Wigneswaran J R, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007; 13 422-430
19 Hillege H L, Nitsch D, Pfeffer M A. et al . Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113 671-678
20 Hoppe U C, Bohm M, Dietz R. et al . Guidelines for therapy of chronic heart failure. Z Kardiol. 2005; 94 488-509
21 Horwich T B, Fonarow G C, Hamilton M A, MacLellan W R, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002; 39 1780-1786
22 Januzzi Jr J L, Camargo C A, Anwaruddin S. et al . The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005; 95 948-954
23 Jessup M, Brozena S. Heart failure. New Engl J Med. 2003; 348 2007-2018
24 Jourdain P, Jondeau G, Funck F. et al . Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007; 49 1733-1739
25 Kempf T, Eden M, Strelau J. et al . The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006; 98 351-360
26 Kempf T, von Haehling S, Peter T. et al . Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007; 50 1054-1060
27 Klein L, O’Connor C M, Leimberger J D. et al . Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005; 111 2454-2460
28 Konstam M A, Gheorghiade M, Burnett Jr J C. et al . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297 1319-1331
29 Lassus J, Harjola V P, Sund R. et al . Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007; 28 1841-1847
30 Latini R, Masson S, Anand I S. et al . Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007; 116 1242-1249
31 Latini R, Masson S, Wong M. et al . Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006; 119 70 e23-e30
32 Lee W H, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986; 73 257-267
33 Levy W C, Mozaffarian D, Linker D T. et al . The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113 1424-1433
34 Maisel A, Hollander J E, Guss D. et al . Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004; 44 1328-1333
35 Maisel A, Mueller C, Adams Jr K. et al . State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10 824-839
36 Maisel A S, Krishnaswamy P, Nowak R M. et al . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med. 2002; 347 161-167
37 Mann D L, Bristow M R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005; 111 2837-2849
38 Masson S, Latini R, Anand I S. et al . Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; 52 1528-1538
39 Moe G W, Howlett J, Januzzi J L, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007; 115 3103-3110
40 Morrow D A, de Lemos J A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115 949-952
41 Mueller C, Scholer A, Laule-Kilian K. et al . Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. New Engl J Med. 2004; 350 647-654
42 Nickel N, Kempf T, Tapken H. et al . Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Resp Crit Care Med. 2008; 178 534-541
43 Pascual-Figal D A, Hurtado-Martinez J A, Redondo B, Antolinos M J, Ruiperez J A, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007; 9 518-524
44 Paulus W J, Tschöpe C, Sanderson J E. et al . How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28 2539-2550
45 Peacock W FT, De Marco T, Fonarow G C. et al . Cardiac troponin and outcome in acute heart failure. New Engl J Med. 2008; 358 2117-2126
46 Redfield M M, Rodeheffer R J, Jacobsen S J, Mahoney D W, Bailey K R, Burnett C Jr J. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004; 109 3176-3181
47 Rehman S U, Mueller T, Januzzi L Jr J. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008; 52 1458-1465
48 Schiffrin E L, Lipman M L, Mann J F. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116 85-97
49 Schlittenhardt D, Schober A, Strelau J. et al . Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res. 2004; 318 325-333
50 Tang W H, Van Lente F, Shrestha K. et al . Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail. 2008; 14 394-399
51 Vasan R S, Benjamin E J, Larson M G. et al . Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002; 288 1252-1259
52 Weinberg E O, Shimpo M, De Keulenaer G W. et al . Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106 2961-2966
53 Weinberg E O, Shimpo M, Hurwitz S, Tominaga S, Rouleau J L, Lee R T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107 721-726
54 Wollert K C, Kempf T, Lagerqvist B. et al . Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007; 116 1540-1548
55 Wollert K C, Kempf T, Peter T. et al . Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007; 115 962-971
56 Wright S P, Doughty R N, Pearl A. et al . Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003; 42 1793-1800
57 Xu J, Kimball T R, Lorenz J N. et al . GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006; 98 342-350

Prof. Dr. med. Kai C. Wollert

Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Telefon: 0511/532-4055

Fax: 0511/532-5307

eMail: wollert.kai@mh-hannover.de